MDM2 gene polymorphisms and risk of classic Kaposi’s sarcoma among Iranian patients

Sajad Varmazyar, Sayed Mahdi Marashi, Zabihollah Shoja, Maria Lina Tornesello, Franco M. Buonaguro, Shohreh Shahmahmoodi, Zahra Safaie-Naraghi, Somayeh Jalilvand

Research output: Contribution to journalArticlepeer-review


A single-nucleotide polymorphism (SNP) in the promoter region of MDM2 (SNP309T>G, rs2279744) has been shown to increase the expression of the MDM2 protein in various cancer types. However, only one study has analyzed the role of the MDM2 polymorphism in the development of Kaposi’s sarcoma (KS). The association of MDM2 SNP309 with classic KS risk was evaluated in 79 Iranian patients with classic KS and 123 healthy controls. The MDM2 SNP309 was genotyped using PCR and restriction fragment length polymorphism methods. No significant correlation was found between the SNP309 polymorphism in MDM2 promoter and classic KS risk. There was no significant correlation between gender and disease stage. However, a significant association was found between SNP309 GG genotype and younger age (≤50 years) (odds ratio 9.5, 95% confidence intervals 1.5–60, p = 0.03). Our findings support no major role for the MDM2 SNP309 in KS development although it might influence the clinical outcome of KS in younger patients.

Original languageEnglish
Pages (from-to)157-163
Number of pages7
JournalMedical Microbiology and Immunology
Issue number2
Publication statusPublished - Apr 1 2017


  • Kaposi’s sarcoma
  • MDM2
  • Risk factor
  • Single-nucleotide polymorphism

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Microbiology (medical)


Dive into the research topics of 'MDM2 gene polymorphisms and risk of classic Kaposi’s sarcoma among Iranian patients'. Together they form a unique fingerprint.

Cite this